Search hospitals > Massachusetts > Worcester
UMass Memorial Medical Center - University Campus
Claim this profileWorcester, Massachusetts 01605
Global Leader in Cancer
Global Leader in Leukemia
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Lymphoma
175 reported clinical trials
13 medical researchers
Summary
UMass Memorial Medical Center - University Campus is a medical facility located in Worcester, Massachusetts. This center is recognized for care of Cancer, Leukemia, Lung Cancer, Recurrence, Lymphoma and other specialties. UMass Memorial Medical Center - University Campus is involved with conducting 175 clinical trials across 392 conditions. There are 13 research doctors associated with this hospital, such as Stefanie R. Lowas, William V. Walsh, Ajit Puri, MD, and Kriti Mittal, MD, MS.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Leukemia
Global LeaderStage II
Stage IV
Stage III
Top PIs
Stefanie R. LowasUMass Memorial Medical Center - University Campus7 years of reported clinical research
Studies Tumors
Studies Rhabdomyosarcoma
22 reported clinical trials
67 drugs studied
William V. WalshUMass Memorial Medical Center - University Campus4 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
19 reported clinical trials
34 drugs studied
Ajit Puri, MDUniversity of Massachusetts3 years of reported clinical research
Studies Stroke
Studies Ischemic Stroke
12 reported clinical trials
22 drugs studied
Kriti Mittal, MD, MSUMass Memorial Medical Center - University Campus4 years of reported clinical research
Studies Cancer
Studies Prostate Cancer
7 reported clinical trials
19 drugs studied
Clinical Trials running at UMass Memorial Medical Center - University Campus
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Squamous Cell Carcinoma
Osteosarcoma
Germ Cell Tumors
Rhabdomyosarcoma
Non-Hodgkin's Lymphoma
Ovarian Tumors
BAY2927088
for Non-Small Cell Lung Cancer
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building plans (genes) for this protein in cancer cells leads to a production of abnormal HER2 and therefore abnormal cell growth and division. The study treatment, BAY 2927088, is expected to block the mutated HER2 protein which may stop the spread of NSCLC. The main purpose of this study is to learn how well BAY 2927088 works and how safe it is compared with standard treatment, in participants who have advanced NSCLC with specific genetic changes called HER2 mutations. The study participants will receive one of the study treatments: * BAY 2927088 twice every day as a tablet by mouth, or * Standard treatment in cycles of 21 days via infusion ("drip") into the vein. The treatment will continue for as long as participants benefit from it without any severe side effects or until they or their doctor decide to stop the treatment. During the study, the doctors and their study team will: * take imaging scans, including CT, PET, MRI, and X-rays, of different parts of the body to study the spread of cancer * check the overall health of the participants by performing tests such as blood and urine tests, and checking * heart health using an electrocardiogram (ECG) * perform pregnancy tests for women * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
Recruiting2 awards Phase 33 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at UMass Memorial Medical Center - University Campus?
UMass Memorial Medical Center - University Campus is a medical facility located in Worcester, Massachusetts. This center is recognized for care of Cancer, Leukemia, Lung Cancer, Recurrence, Lymphoma and other specialties. UMass Memorial Medical Center - University Campus is involved with conducting 175 clinical trials across 392 conditions. There are 13 research doctors associated with this hospital, such as Stefanie R. Lowas, William V. Walsh, Ajit Puri, MD, and Kriti Mittal, MD, MS.